A. Atezolizumab + chemotherapy B. Avelumab + axitinib C. Durvalumab + chemotherapy D. Pembrolizumab + lenvatinib E. Unsure

A. Continue durvalumab B. Hold durvalumab C. Initiate corticosteroids D. Initiate infliximab E. Unsure

A. Initial management is the same for both conditions: close monitoring and self-isolation B. Corticosteroids improve survival for both immune-related pneumonitis and COVID-19 pneumonia C. Anti–interleukin-6 therapy improves survival for both immune-related pneumonitis and COVID-19 pneumonia D. Immune-related pneumonitis has multifocal ground-glass opacities on computed tomography (CT) scans, but COVID-19 pneumonia presents more like a usual bacterial pneumonia E. Unsure

A. You should let your care provider know if you experience any unusual symptoms such as shortness of breath, fever, rash, or diarrhea B. Your disease response to ICI may take longer than with typical chemotherapy or radiation therapy C. You will have to discontinue ICI therapy if you develop an immune-related adverse event D. Immune-related adverse events typically occur within 6 weeks to 6 months of ICI initiation but can also occur up to a year after initiation and even after therapy has been completed E. Unsure

A. The team works together to determine the best course of care for the patient B. The nurse practitioner prescribes a systemic corticosteroid for the patient's grade 2 immune-related adverse event C. The nurse reports to the pharmacist that the patient told her his medications are “all the same” D. The nurse practitioner places a referral for a dermatology consult E. Unsure